TNGX NASDAQ
Tango Therapeutics, Inc.
1W: -17.6%
1M: -9.0%
3M: -19.4%
YTD: +148.9%
1Y: +186.1%
3Y: +215.3%
5Y: +75.9%
$22.23
-0.66 (-2.88%)
After Hours: $22.56 (+0.33, +1.48%)
Weekly Expected Move ±12.7%
$17
$20
$23
$26
$29
Credit Risk of going bust: lower than 53% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.8%), Tango Therapeutics, Inc. would be worth roughly what it owes.
Total debt $32.0M against a stock market value of $3.86B.
Distance to default 5.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 93.4%; Altman Z'' 25.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.8%), Tango Therapeutics, Inc. would be worth roughly what it owes.
Total debt $32.0M against a stock market value of $3.86B.
Distance to default 5.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 93.4%; Altman Z'' 25.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
5 bullish
17 neutral
5 bearish
Articles (7d)
27
Daily Sentiment (7 Days)
Articles (100)
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
TNGX Jan 2027 37.000 call (TNGX270115C00037000) stock price, news, quote and history - Yahoo Finance UK
TNGX Feb 2027 29.000 put (TNGX270219P00029000) stock price, news, quote and history - Yahoo Finance Australia
Tango Therapeutics, Inc. (TNGX) Options Chain - Yahoo Finance - Yahoo! Finance Canada
TNGX Dec 2027 30.000 put (TNGX271217P00030000) Stock Price, News, Quote & History - Yahoo! Finance Canada
TNGX Jun 2027 40.000 call (TNGX270617C00040000) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada
TNGX Nov 2026 12.000 put (TNGX261120P00012000) interactive stock chart - Yahoo Finance UK
Tango Therapeutics Sees Unusually Large Options Volume (NASDAQ:TNGX)
TNGX 8-K & SEC Filings - Yahoo Finance
TNGX Jun 2027 40.000 call (TNGX270617C00040000) Stock Price, News, Quote & History - Yahoo! Finance Canada
TNGX Nov 2026 12.000 put (TNGX261120P00012000) Stock Historical Prices & Data - Yahoo! Finance Canada
TNGX Nov 2026 12.000 put (TNGX261120P00012000) Interactive Stock Chart - Yahoo! Finance Canada
TNGX Nov 2026 38.000 call (TNGX261120C00038000) Interactive Stock Chart - Yahoo! Finance Canada
TNGX Nov 2026 39.000 call (TNGX261120C00039000) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”
Tango Therapeutics stock falls despite positive cancer trial data
Tango Therapeutics stock falls despite positive cancer trial data - Investing.com
At nine months, 88% of 22 pancreatic cancer patients were alive without their cancer worsening. - Stock Titan
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
TNGX Feb 2027 29.000 put (TNGX270219P00029000) Stock Price, News, Quote & History - Yahoo! Finance Canada
TNGX Nov 2026 15.000 call (TNGX261120C00015000) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
TNGX Nov 2026 22.000 put (TNGX261120P00022000) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada
TNGX Nov 2026 15.000 call (TNGX261120C00015000) Stock Price, News, Quote & History - Yahoo! Finance Canada
TNGX Nov 2026 25.000 put (TNGX261120P00025000) Interactive Stock Chart - Yahoo! Finance Canada
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
TNGX Nov 2026 45.000 put (TNGX261120P00045000) stock price, news, quote and history - Yahoo Finance UK
TNGX Nov 2026 45.000 put (TNGX261120P00045000) interactive stock chart - Yahoo Finance UK
TNGX Nov 2026 45.000 put (TNGX261120P00045000) stock historical prices and data - Yahoo Finance UK
TNGX Nov 2026 20.000 call (TNGX261120C00020000) stock price, news, quote and history - Yahoo Finance UK
Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run
TNGX Nov 2026 20.000 call (TNGX261120C00020000) Stock Price, News, Quote & History - Yahoo! Finance Canada
TNGX Nov 2026 13.000 put (TNGX261120P00013000) stock price, news, quote and history - Yahoo Finance UK
TNGX Nov 2026 13.000 put (TNGX261120P00013000) Interactive Stock Chart - Yahoo! Finance Canada
TNGX Nov 2026 13.000 put (TNGX261120P00013000) interactive stock chart - Yahoo Finance UK
TNGX Nov 2026 21.000 put (TNGX261120P00021000) Stock Price, News, Quote & History - Yahoo! Finance Canada
TNGX Nov 2026 21.000 put (TNGX261120P00021000) stock price, news, quote and history - Yahoo Finance UK
Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?
Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? - Yahoo Finance
TNGX Nov 2026 26.000 put (TNGX261120P00026000) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Congress Asset Management Co. Acquires 97,708 Shares of Tango Therapeutics, Inc. $TNGX
Most shorted stocks on Wall Street
Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.4% – Here’s What Happened
Most and least shorted mid- to mega-cap healthcare stocks at the end of September
Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares - Stock Titan
Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX
(TNGX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Yahoo Finance
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan
Most shorted stocks on Wall Street
Most and least shorted mid- to mega-cap healthcare stocks at the end of August
Tango Therapeutics (TNGX) Stock Looks Stretched After Its 236% Run - simplywall.st
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX
Tango Therapeutics, Inc. $TNGX Shares Sold by Bank of America Corp DE
ADAR1 Capital Management LLC Invests $2.40 Million in Tango Therapeutics, Inc. $TNGX
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses - Yahoo Finance
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics Announces Executive Chair Transition
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of “Moderate Buy” by Analysts
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
Tango Therapeutics (NASDAQ:TNGX) Trading Up 6.1% – Should You Buy?
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues - Yahoo Finance
2 Monster Growth Stocks Analysts Think Can Reach New Highs
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? - Yahoo Finance
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts - Zacks Investment Research
This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In.
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics (TNGX) stock soars on pancreatic cancer trial results - MSN
$TNGX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
$TNGX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
TNGX (Nasdaq: TNGX) affiliate files Form 144 to sell 3.5M shares - Stock Titan
Tango Therapeutics stock hits all-time high at 33.19 USD - Investing.com
Tango Therapeutics (TNGX) Stock Could Be 39% Below Fair Value After Trial Data And Offering - simplywall.st
Tango Therapeutics (TNGX) Stock Could Be 39% Below Fair Value After Trial Data And Offering - simplywall.st
Tango Therapeutics (TNGX) Is Up 6.4% After $600 Million Raise Backs Vopimetostat Combo Data - simplywall.st
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD